Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 1 | $209,400 |
| Sells | 31 | $12,611,532 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 19 Nov 2024 16:31 | RVNC | Revance Therapeutics Inc | HOLLANDER DAVID | CMO & Global Therapeutics Lead | 18 Nov 2024 | Sale | 3,908 | 4.17 | 16,296 | D |
| 17 Apr 2024 16:34 | RVNC | Revance Therapeutics Inc | JORDAN ERICA | Chief Commercial Officer | 16 Apr 2024 | Sale | 2,392 | 3.8028 | 9,096 | D |
| 19 Mar 2024 18:45 | RVNC | Revance Therapeutics Inc | SJUTS DUSTIN S | President | 18 Mar 2024 | Sale | 9,211 | 5.0425 | 46,446 | D |
| 19 Mar 2024 18:44 | RVNC | Revance Therapeutics Inc | MOXIE DWIGHT | CLO & GC | 18 Mar 2024 | Sale | 8,125 | 5.0426 | 40,971 | D |
| 19 Mar 2024 18:44 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 18 Mar 2024 | Sale | 9,361 | 5.0426 | 47,204 | D |
| 08 Mar 2024 16:33 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 06 Mar 2024 | Purchase | 30,000 | 6.98 | 209,400 | D |
| 07 Sep 2023 17:37 | RVNC | Revance Therapeutics Inc | MOXIE DWIGHT | SVP, GC & Secretary | 06 Sep 2023 | Sale | 11,000 | 17.064 | 187,704 | D |
| 07 Sep 2023 17:37 | RVNC | Revance Therapeutics Inc | MOXIE DWIGHT | SVP, GC & Secretary | 05 Sep 2023 | Sale | 23,853 | 17.8141 | 424,920 | D |
| 04 Aug 2023 17:07 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 03 Aug 2023 | Sale | 26,279 | 22.5713 | 593,151 | D |
| 05 Jul 2023 21:11 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 03 Jul 2023 | Sale | 1,701 | 25.04 | 42,593 | D |
| 05 Jul 2023 21:11 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 03 Jul 2023 | Sale | 26,279 | 24.9375 | 655,333 | D |
| 20 Jun 2023 16:25 | RVNC | Revance Therapeutics Inc | KOLAJA CAREY OCONNOR | Director | 15 Jun 2023 | Sale | 2,500 | 28.24 | 70,600 | D |
| 13 Jun 2023 20:09 | RVNC | Revance Therapeutics Inc | SJUTS DUSTIN S | President | 09 Jun 2023 | Sale | 5,000 | 30.8192 | 154,096 | D |
| 13 Jun 2023 20:09 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 09 Jun 2023 | Sale | 31,279 | 30.7212 | 960,928 | D |
| 05 Jun 2023 18:06 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 02 Jun 2023 | Sale | 500 | 31 | 15,500 | D |
| 05 Jun 2023 18:06 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 01 Jun 2023 | Sale | 2,701 | 30.57 | 82,570 | D |
| 16 May 2023 20:29 | RVNC | Revance Therapeutics Inc | MOXIE DWIGHT | SVP, GC & Secretary | 15 May 2023 | Sale | 21,401 | 34.5469 | 739,338 | D |
| 16 May 2023 20:29 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 15 May 2023 | Sale | 21,401 | 34.5469 | 739,338 | D |
| 16 May 2023 20:29 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 15 May 2023 | Sale | 70,447 | 34.5469 | 2,433,725 | D |
| 16 May 2023 20:29 | RVNC | Revance Therapeutics Inc | SJUTS DUSTIN S | President | 15 May 2023 | Sale | 21,015 | 34.5469 | 726,003 | D |
| 02 May 2023 16:01 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 01 May 2023 | Sale | 3,201 | 31.7 | 101,472 | D |
| 04 Apr 2023 16:24 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 03 Apr 2023 | Sale | 3,201 | 32.15 | 102,912 | D |
| 09 Mar 2023 21:46 | RVNC | Revance Therapeutics Inc | MOXIE DWIGHT | SVP, GC & Secretary | 09 Mar 2023 | Sale | 18,496 | 31.5863 | 584,220 | D |
| 09 Mar 2023 21:46 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 09 Mar 2023 | Sale | 18,517 | 31.5863 | 584,884 | D |
| 09 Mar 2023 21:45 | RVNC | Revance Therapeutics Inc | SJUTS DUSTIN S | President | 09 Mar 2023 | Sale | 21,508 | 31.5863 | 679,358 | D |
| 09 Mar 2023 21:45 | RVNC | Revance Therapeutics Inc | FOLEY MARK J | CEO | 09 Mar 2023 | Sale | 70,390 | 31.5863 | 2,223,360 | D |
| 02 Mar 2023 21:25 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 01 Mar 2023 | Sale | 3,201 | 33.5 | 107,234 | D |
| 02 Feb 2023 21:38 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 01 Feb 2023 | Sale | 3,201 | 34.6 | 110,755 | D |
| 23 Jan 2023 17:35 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 20 Jan 2023 | Sale | 1,000 | 31 | 31,000 | D |
| 10 Jan 2023 20:06 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 09 Jan 2023 | Sale | 1,000 | 30 | 30,000 | D |
| 10 Jan 2023 20:06 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 09 Jan 2023 | Sale | 1,000 | 28 | 28,000 | D |
| 10 Jan 2023 20:06 | RVNC | Revance Therapeutics Inc | SCHILKE TOBIN | CFO | 09 Jan 2023 | Sale | 1,701 | 25 | 42,525 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)